Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. reports operating results and product-development updates for a diversified technology developer and manufacturer trading on the OTCQB under ADMT. Company updates focus on three activity areas: proprietary electronic medical devices, design, engineering, regulatory and manufacturing services, and eco-friendly water-based formulations.
Recurring news themes include fiscal quarter and annual revenue trends, segment performance in electronics, engineering services and chemical formulations, and research and development for the Sonotron and Vet-Sonotron non-invasive musculoskeletal pain therapy technologies. Releases also cover contract engineering and manufacturing services, medical-device development, and the regulatory pathway for a human medical version of the Sonotron technology.
ADM Tronics (OTCQB:ADMT) reported third-quarter fiscal 2026 results for the period ended December 31, 2025, with quarterly revenue of $803,088 and nine-month revenue of $2,664,261. The company cited ongoing R&D on a non-invasive musculoskeletal pain therapy device and plans to submit a 510(k) when development is complete.
Quarter loss from operations was $84,441 and nine-month income from operations was $27,346. Complete results appear in the company Form 10-Q.
ADM Tronics (OTCQB:ADMT) reported second fiscal quarter results for the period ended September 30, 2025. The company reported six-month revenues of $1,861,173 (an increase of over 9.6% year-over-year) and quarter revenues of $887,498 (an increase of over 5.6% versus the prior-year quarter).
Income from operations was $111,787 for the six months and $2,553 for the quarter, compared with $118,262 and a loss of $45,858 in the comparable prior periods. The company continues R&D on its Sonotron non-invasive therapeutic device and intends to submit a 510(k) premarket notification to the FDA after engineering is finalized. Full financials are available in the company Form 10-Q for September 30, 2025.
ADM Tronics (OTCQB:ADMT) reported strong Q1 FY2026 results with revenues reaching $973,675, marking a 13.5% increase from the same period last year. The company's electronics segment led growth with a 25% increase, while the chemical segment grew by 5%. Net income rose to $327,634 from $272,168 year-over-year.
The company continues development of its medical Sonotron® device for human pain treatment, planning an FDA 510(k) submission. This non-invasive therapy uses pulsed radio frequency for treating chronic and acute musculoskeletal conditions. ADMT has already launched the Vet-Sonotron® for veterinary applications and is seeking distributors for animal markets.
ADM Tronics (OTCQB:ADMT) reported improved financial results for fiscal year 2025. The company achieved an 8% revenue increase to $3,197,110, driven by growth in engineering services ($232,469) and electronics manufacturing. Gross profit margin improved to 44% from 38% year-over-year.
Operating losses decreased significantly by 89% to $94,024, while net loss improved by 86% to $123,056. The company focused R&D efforts on developing a medical version of Sonotron®, a non-invasive pain treatment technology using pulsed radio frequency, and launched Vet-Sonotron® for veterinary applications.
ADM Tronics (OTCQB:ADMT) reported financial results for Q2 FY2025. Revenues increased 12% to $1,697,881 for the six months ended September 30, 2024, compared to $1,516,821 in the same period last year. The company posted income from operations of $118,423 versus a loss of $365,446 in the prior year period. For Q2, revenues grew 11% to $840,036, though operating loss was $45,858 compared to a $228,105 loss last year. The improvement was driven by increased revenues in engineering and chemical segments. The company continues R&D on its proprietary non-invasive musculoskeletal pain therapy device, planning an FDA 510(k) submission.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reports positive financial results for the first quarter of Fiscal Year 2025 ended June 30, 2024. Key highlights include:
- Revenue increased by 12% to $857,845 compared to $762,689 in the same period last year
- Net profit of $272,168, a significant improvement from a net loss of $132,261 in the previous year
- Profit from operations of $164,281, compared to a loss of $137,796 in the same quarter last year
- Gross profit increased to $520,903 from $325,142
ADMT completed R&D for its Vet-Sonotron® device and is advancing the human medical version. The company plans to pursue FDA 510(k) submission for the human Sonotron®, targeting non-drug pain treatment.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported results for fiscal year ended March 31, 2024. Key highlights:
- Revenues decreased 19% to $2,965,406
- Gross profit fell to $1,116,422 (38% margin) from $1,657,902 (45% margin)
- Net loss widened to $877,222 from $96,322
- R&D expenses increased to $576,903 from $541,184
- Focused on finalizing Vet-Sonotron® technology for veterinary market
- Developing medical version of Sonotron® for human use
- Reduced engineering services revenues due to prioritizing proprietary product development
- Recorded reserve for past due accounts receivables
- Faced challenges from inflation and supply chain issues
Summary not available.
Summary not available.
Summary not available.